# Can Pregabalin Reduce the Frequency and Severity of Dry Eye Symptoms After Laser-assisted in Situ Keratomileusis?

> **NCT02701764** · PHASE2,PHASE3 · COMPLETED · sponsor: **University of Miami** · enrollment: 43 (actual)

## Conditions studied

- Dry Eye

## Interventions

- **DRUG:** Pregabalin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02701764
- **Lead sponsor:** University of Miami
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-07-26
- **Primary completion:** 2018-12-01
- **Final completion:** 2018-12-01
- **Target enrollment:** 43 (ACTUAL)
- **Last updated:** 2019-11-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02701764

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02701764, "Can Pregabalin Reduce the Frequency and Severity of Dry Eye Symptoms After Laser-assisted in Situ Keratomileusis?". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02701764. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*